Exhibit 16.1
 
July 21, 2021
 
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549-7561
 
Ladies and Gentlemen:
 
We have read VistaGen Therapeutics, Inc.’s statements included under Item 4.01 of its Form 8-K dated July 21, 2021, and are in agreement with the statements contained therein concerning our firm in response to Item 304(a) of Regulation S-K.
 
Very truly yours,
 
/s/ OUM & Co. LLP